Press releases
Read press releases issued by GlaxoSmithKline Pharmaceuticals Limited.
Our Global press releases can be viewed on our global website.
-
GlaxoSmithKline Pharmaceuticals Limited (GSK) announces its financial results for the third quarter ended 31st December 2023
GlaxoSmithKline Pharmaceuticals Limited (GSK) announces its financial results for the third quarter ended 31st December 2023
-
GSK registers 5% Growth
General Medicine grows 5% and Vaccines 10% led by Shingrix
-
General Medicines delivers 4% revenue growth despite NLEM impact along with a sequential recovery in the vaccines business
General Medicines delivers 4% revenue growth despite NLEM impact along with a sequential recovery in the vaccines business
-
Amitabh Bachchan partners with GSK for shingles awareness and prevention
Amitabh Bachchan partners with GSK for shingles awareness and prevention
-
GlaxoSmithKline Pharmaceuticals Limited reported improved profitability with continued momentum across General medicines and Specialty; Declares annual dividend of Rs. 32
GlaxoSmithKline Pharmaceuticals Limited reported improved profitability with continued momentum across General medicines and Specialty
-
GSK launches Shingrix in India- A vaccine for the prevention of shingles in adults aged 50 years and above
GSK launches Shingrix in India- A vaccine for the prevention of shingles in adults aged 50 years and above
-
Continued momentum across General Medicines and Specialty
Continued momentum across General Medicines and Specialty
-
GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended September 30, 2022
GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended September 30, 2022
-
New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over
New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over
-
Media release: Q1 of 2022-23
GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended June 30, 2022
-
GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended June 30, 2022
GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended June 30, 2022.
-
GlaxoSmithKline Pharmaceuticals Limited announces results for the full year ended March 31, 2022
GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the year ended March 31, 2022.
-
GSK launches once daily, single inhaler-triple therapy for COPD patients for the first time in India
GSK launched Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India
-
GSK and MS Dhoni team up for 6 in 1 vaccination awareness campaign
Mahendra Singh Dhoni, India's legendary former cricket captain and a devoted father, now teams up with GSK to raise awareness
-
GlaxoSmithKline Pharmaceuticals Limited delivers strong financials led by Pharma growth
GlaxoSmithKline Pharmaceuticals Ltd today declared its financial results for the quarter ended December 31, 2021
-
GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended September 30, 2021
GlaxoSmithKline Pharmaceuticals Ltd today declared its financial results for the quarter ended September 30, 2021
-
GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended June 30, 2021
GlaxoSrnithircline Pharmaceuticals Limited today declared its financial results for the quarter ended June 30, 2021
-
GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter and full year ended March 31, 2021
GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended 31st March 2021
-
GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended December 31, 2020
GlaxoSmithKline Pharmaceuticals Limited today declared its f inancial results for the quarter ended 31 st December 2020
-
GSK, PATH and Bharat Biotech sign product transfer agreement to help ensure long-term supply of ground-breaking malaria vaccine
GSK, PATH, and Bharat Biotech (BBIL) today announced the signing of a product transfer agreement for the malaria vaccine
